Chimeric Therapeutics Limited Price Chart
Chimeric Therapeutics Limited CHM.XA Financial and Trading Overview
Chimeric Therapeutics Limited stock price | 0.02 AUD |
Previous Close | 0.04 AUD |
Open | 0.04 AUD |
Bid | 0.04 AUD x N/A |
Ask | 0.04 AUD x N/A |
Day's Range | 0.04 - 0.04 AUD |
52 Week Range | 0.03 - 0.09 AUD |
Volume | 117.35K AUD |
Avg. Volume | 152.9K AUD |
Market Cap | N/A |
Beta (5Y Monthly) | 1.807311 |
PE Ratio (TTM) | N/A |
EPS (TTM) | 0 AUD |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
CHM.XA Valuation Measures
Enterprise Value | 12.55M AUD |
Trailing P/E | N/A |
Forward P/E | N/A |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | N/A |
Price/Book (mrq) | 1.054054 |
Enterprise Value/Revenue | 2.197 |
Enterprise Value/EBITDA | -0.798 |
Trading Information
Chimeric Therapeutics Limited Stock Price History
Beta (5Y Monthly) | 1.807311 |
52-Week Change | -57.77% |
S&P500 52-Week Change | 20.43% |
52 Week High | 0.09 AUD |
52 Week Low | 0.03 AUD |
50-Day Moving Average | 0.05 AUD |
200-Day Moving Average | 0.06 AUD |
CHM.XA Share Statistics
Avg. Volume (3 month) | 152.9K AUD |
Avg. Daily Volume (10-Days) | 153.05K AUD |
Shares Outstanding | N/A |
Float | 290.44M |
Short Ratio | N/A |
% Held by Insiders | 35.40% |
% Held by Institutions | 0% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | N/A |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | June 30, 2022 |
Most Recent Quarter (mrq) | December 31, 2022 |
Next Fiscal Year End | June 30, 2023 |
Profitability
Profit Margin | 0% |
Operating Margin (ttm) | -292.0050% |
Gross Margin | 100.00% |
EBITDA Margin | -275.28% |
Management Effectiveness
Return on Assets (ttm) | -41.19% |
Return on Equity (ttm) | -107.42% |
Income Statement
Revenue (ttm) | 5.71M AUD |
Revenue Per Share (ttm) | 0.01 AUD |
Quarterly Revenue Growth (yoy) | N/A |
Gross Profit (ttm) | 2.62M AUD |
EBITDA | -15722398 AUD |
Net Income Avi to Common (ttm) | -17957048 AUD |
Diluted EPS (ttm) | N/A |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 3.63M AUD |
Total Cash Per Share (mrq) | 0.008 AUD |
Total Debt (mrq) | 0 AUD |
Total Debt/Equity (mrq) | N/A |
Current Ratio (mrq) | 1.406 |
Book Value Per Share (mrq) | 0.037 |
Cash Flow Statement
Operating Cash Flow (ttm) | -19645244 AUD |
Levered Free Cash Flow (ttm) | -13575910 AUD |
Profile of Chimeric Therapeutics Limited
Country | Australia |
State | VIC |
City | Carlton |
Address | 62 Lygon Street |
ZIP | 3053 |
Phone | 61 3 9824 5254 |
Website | https://www.chimerictherapeutics.com |
Industry | |
Sector(s) | |
Full Time Employees | N/A |
Chimeric Therapeutics Limited, a clinical stage cell therapy company, develops and commercializes a range of cell therapies in oncology in Australia. The company develops CHM 0201 (core NK platform) that is in phase I clinical trial for treating solid tumors and hematological malignancies; and CHM 1101 (CLTX CAR T), which is in phase I clinical trial for treating patients with MMP2+ recurrent or progressive glioblastoma. It is also developing CHM 0301 for blood cancers; CHM 1301 (CLTX CAR NK) and CHM 2301 (CDH17 CAR NK) for solid tumors; CHM 1101 (CLTX CAR T) for melanoma, colorectal, and prostate; and CHM 2101 (CDH17 CAR T) for neuroendocrine, colorectal, pancreatic, and gastric. The company was incorporated in 2020 and is based in Carlton, Australia.
Q&A For Chimeric Therapeutics Limited Stock
What is a current CHM.XA stock price?
Chimeric Therapeutics Limited CHM.XA stock price today per share is 0.02 AUD.
How to purchase Chimeric Therapeutics Limited stock?
You can buy CHM.XA shares on the Cboe AU exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Chimeric Therapeutics Limited?
The stock symbol or ticker of Chimeric Therapeutics Limited is CHM.XA.
How many shares does Chimeric Therapeutics Limited have in circulation?
The max supply of Chimeric Therapeutics Limited shares is 0.
What is Chimeric Therapeutics Limited Price to Earnings Ratio (PE Ratio)?
Chimeric Therapeutics Limited PE Ratio is now.
What was Chimeric Therapeutics Limited earnings per share over the trailing 12 months (TTM)?
Chimeric Therapeutics Limited EPS is 0 AUD over the trailing 12 months.